Statistical Issues Arising in AIDS Clinical Trials

By Ellenberg, Susan S.; Finkelstein, Dianne M. et al. | Journal of the American Statistical Association, June 1992 | Go to article overview
Save to active project

Statistical Issues Arising in AIDS Clinical Trials

Ellenberg, Susan S., Finkelstein, Dianne M., Schoenfeld, David A., Journal of the American Statistical Association

The evaluation of treatments for the acquired immune deficiency syndrome (AIDS) and human immunodeficiency virus (HIV)-related disorders has become a large-scale effort in a very short period. AIDS as a disease entity was first noted in 1981, when the Centers for Disease Control (CDC) reported rare forms of pneumonia and skin cancer in young gay men in California and New York (CDC 1981 a). The first "definition" of AIDS, developed by the CDC (1982), appeared in 1982. The virus was isolated in 1983 (Barre-Sinoussi et al. 1983), and tests for the disease-documenting antibodies became available the following year. These developments led to a revised CDC definition of AIDS to include a positive antibody test and a more detailed description of the clinical events (primarily opportunistic infections and malignancies) that formed the syndrome.

The identification and isolation of HIV permitted the initiation of drug development efforts. In 1986 funds were first awarded by the National Institute of Allergy and Infectious Diseases (NIAID) for a national cooperative clinical trials program modeled loosely on the oncology cooperative group model developed at the National Cancer Institute (NCI). The efforts to find a treatment produced the first effective drug, zidovudine (ZDV or AZT), in a surprisingly brief period; The results of a highly positive randomized placebo-controlled trial of AZT were published early in 1987 (Fischl et al. 1987), and the drug was approved for marketing by the Food and Drug Administration (FDA) shortly thereafter.

AIDS is different from other life-threatening diseases for which treatments are routinely studied in clinical trials. First, it is an epidemic. AIDS is an infectious disease for which a substantial proportion of the population is at risk. This circumstance provokes a different mind-set than that associated with other frequently fatal diseases, such as cancer, that affect far greater numbers of individuals. This infectious disease, however, is also a chronic illness. The sense of urgency engendered by the concept of an epidemic is therefore directly confronted with all the complications and delays inherent in studying a chronic disease with survival time as a primary outcome of concern.

Second, AIDS is a new disease. Our understanding of the natural history is growing rapidly, but is still very limited compared to diseases that we have been studying for decades or even centuries. The disease is complicated, with large numbers of potentially fatal sequelae, each of which may require a different therapeutic and/or prophylactic approach. Each new effective regimen itself alters the "natural history"; our success in reducing the incidence of any of these infections results in an increased incidence of other opportunistic diseases.

Finally, the nature of the populations that have borne the brunt of the epidemic is unusual. At least in the United States, AIDS is a disease of homosexuals, of intravenous drug users, of minorities, and of the poor--all groups that are stigmatized to varying degrees by "mainstream" society. Because some of these groups are virtually removed from the health care system, it is difficult to involve them in studies of investigational drugs. The gay population, on the other hand, had become highly politicized over civil rights issues even before AIDS; the advent of the disease has heightened their concerns substantially. Representatives of affected communities have become increasingly vocal regarding issues related to testing of investigational drugs (Harrington 1990; Ellenberg et al., in press).

All these issues generate intense and often conflicting concerns for statisticians designing clinical trials to evaluate AIDS therapies. The development of more efficient clinical trials designs long has been a research topic of interest to statisticians, and the impact of the pertinent issues on trial designs have been discussed by Byar et al.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Statistical Issues Arising in AIDS Clinical Trials


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?